A modern choice for patients with hypertension: the possibility of new calcium antagonist of III generation
https://doi.org/10.20996/1819-6446-2015-11-5-535-542
Abstract
Features and possibility of application of the calcium channel blocker lercanidipine in cardiology practice are discussed. The use of lercanidipine in patients with hypertension is supported by extensive evidences. The use of lercanidipine in certain categories of patients, including patients receiving combination therapy is also considered. The safety of lercanidipine in cardiac patients is discussed separately.
About the Authors
E. I. Emelina
Pirogov Russian National Research Medical University. Ostrovitianova ul., 1, Moscow, 117997 Russia
Russian Federation
Russian Federation
G. E. Gendlin
Pirogov Russian National Research Medical University. Ostrovitianova ul., 1, Moscow, 117997 Russia
Russian Federation
Russian Federation
References
1. National guidelines on the diagnosis and treatment of hypertension. Sistemnye Gipertenzii 2010; 3: 5-26. In Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии. Системные Гипертензии 2010; 3: 5-26).
2. Mancia G., Fagard R., Narkiewicz K. et al.; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-357.
3. Mancia G., Laurent S., Agabiti-Rosei E. et al.; European Society of Hypertension. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121-58.
4. Robles N.R., Canelada J.A., Iglesias M. et al. Evaluation of lercanidipine in the general practice setting. An Med Interna 2003; 20(6): 282-6.
5. McClellan K., Jarvis B. Lercanidipine. A review of its use in Hypertension. Drugs 2000; 60 (5): 1123-40.
6. Taddei S., Virdis A., Ghiadoni L. et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarisation in essential hypertension. Hypertension 2003; 41 (4): 950-5.
7. Preobrazenskii DV, Sidorenko BA, Dedov IS et al. Lercanidipine a new calcium antagonist of the third generation: clinical pharmacology and experience of use in the treatment of hypertension. Russkiy Meditsinskiy Zhurnal 2006; 20: 1411-8. In Russian (Преображенский Д.В., Сидоренко Б.А., Дедова И.С. и др. Лерканидипин – новый антагонист кальция третьего поколения: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Русский Медицинский Журнал 2006; 20: 1411-8).
8. Burnier M., Gasser U.E. Efficacy and tolerability of lercaniclipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother 2007; 8(14): 2215-23.
9. Herbette L., Vecchiarelli M., Sartani A. et al. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998; Suppl 2: 10-7.
10. Notarbartolo A., Rengo F., Scafidi V. et al. Long-term effects of lercanidipine on the lipoprotein and apolipopprotein profile of patients with mild-to-moderate essential hypertension. Curr Ther Res 1999; 60: 228-36.
11. Schwinger R.H.G., Schmidt-Mertens A. The new lipophilic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects. Dtsch Med Wochenschr 2002; 127 Suppl 1: s13.
12. Zanchetti A., Bond M.G., Hennig M. et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-7.
13. Fagard R.H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084-91.
14. Bang L., Chapman T., Goa K. Lercanidipine – a review of its efficacy in management of hypertension. Drugs 2003; 22: 2449-72.
15. NICE. Hypertension: clinical management of primary hypertension in adults (Clinical guidelines, CG127 Issued: August 2011). Available at: http://guidance.nice.org.uk/CG127. Accessed by 20.10.2015.
16. Luque M., Ruilope L.M., Tamargo J. et al. Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN study. Am J Hypertens 2004; 20 Suppl 4: S163.
17. Ninci M.A., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997; 29: S40-4.
18. Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow release nifedipine. J Cardiovasc Pharmacol 1997; 29: S31-5.
19. Romito R., Pansini M., Perticone F. et al. Comparative effect of lercanidipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: The Lercanidipine in Adults (LEAD) Study. J Clin Hyprtens 2003; 5 (4): 249-53.
20. Cherubini A., Fabris F., Ferrari E. et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003 ;3: 203-12.
21. Zanchetti A. Emerging data on calcium-channel blockers: the COHORT study. Clin Cardiol 2003; 26 (Suppl 2): II 17-20.
22. Poncelet P., Ribstein J., Goullard L. et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol (Paris) 2004; 53(3):123-30.
23. Leonetti G., Magnani B., Pessina A.C. et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932-40.
24. Millar-Craig M., Shaffu B., Greenough A. et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens 2003; 17: 799-806.
25. Seravalle G., Stella M.L., Foglia G. et al. Temporal profile of antihypertensive drug-induced regression of cardiac and vascular structural alterations in hypertension. J Hypertens 2002; 20: S190.
26. Barbagallo M., Barbagallo S.G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging (Milano) 2000; 12: 375-9.
27. Rengo F., Romis L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J Cardiovasc Pharmacol 1997; 29:S54-8.
28. Fogari R., Mugellini A., Zoppi A. et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-9.
29. Mackenzie I.S., McEniery C.M., Dhakam Z. et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54: 409-13.
30. Borghi C., Prandin M.G., Dormi A. et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl 2003; 1: 14-21.
31. Barrios V., Navarro A., Esteras A. et al.; Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11(2):95-100.
32. Viviani G.L. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002; 40: 133-9.
33. Marx A., Lichtenthal A., Milbredt C. et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. J Hypertens 2004; 22 Suppl 2: S236.
34. Barrios V., Calderon A., Navarro A. et al. Lercanidipine is an effective and well tolerated drug in essential hypertension, independently of the cardiovascular risk. The Laura study. J Hypertens 2004; 22 Suppl 2: S235
35. Acanfora D., Trojano L., Gheorghiade M. et al. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): 444-53.
36. Taddei S., Virdis A., Ghiadoni L. et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarisation in essential hypertension. Hypertension 2003; 41 (4): 950-5.
37. Weir M.R. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 2003; 5: 330-5.
38. Bellosta S., Bernini F. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atheroscler Rep 2000; 2: 76-81.
39. Leonetti G. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press 1999; 8: 92-101.
40. Zanchetti A. Calcium channel blockers in hypertension. Chapt. 22. In: Black H.R., Elliott W.J., eds. Hypertension: a Companion to Braunwald’s Heart Disease. Philadelphia; Saunders: 2012: 204-18.
41. Fogari R., Mugellini A., Zoppi A. et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-9.
42. Notarbartolo A., Rengo F., Scafidi V. et al. Long-term effects of lercanidipine on the lipoprotein and aholipoprotein profile of patients with mild to moderate essential hypertension. Curr Ther Res 1999; 60 (4): 228-36.
43. Viviani G.L. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002; 40: 133-9.
44. Sabbatini M., Leonardi A., Testa R. et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-9.
45. Dalla Vestra M., Pozza G., Mosca A. et al. Effect of lercanidpine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diabetes Nutr Metab 2004; 17: 259-66.
46. Burnier M. Renal protection with calcium antagonists: the role of lercanidipine. Curr Med Res Opin 2013; 29(12): 1727-35.
47. Luque M., Ruilope L.M., Tamargo J. et al. Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN study. Am J Hypertens 2004; 20: Suppl 4: S163
48. Aronow W.S., Fleg J.L., Pepine C.J. et al.; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011; 123(21): 2434-506.
49. Taddei S., Virdis A., Ghiadoni L. et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41: 950-5.
50. Hollenberg N.K. Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials. Am J Hypertens 2002; 15: 58A-59A.
51. Robles N.R., Pastor L., Manjon M. et al. Lercanidipine in diabetic patients with renal failure // Nefrologia. 2004. V. 24. P. 338-343.
52. Robles N.R., Romero B., Garcia de Vinuesa E. et al. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32(2): 192-7.
53. Mallion J.M., Allaert F.A., Scart-Gres C. et al. Variations in the frequency of lower limb oedema in patients recieving lercanidipine in adjunction to their antihypertensive treatment. J Hypertens 2004; 22 Suppl 2: S269
54. Cicero A.F.G., Gerocarni B., Rosticci M., Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012; 34(2): 113-7.
55. Guillen V.F.G., Abellan J., Llisterri J.L. et al. Efficacy and safety of lercanidipine in combination with enalapril in HBP. Preliminary results of ZANYCONTROL study group. Am J Hypertens 2003; 16: 115A.
56. Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005; 1(3): 173-82.
Review
For citations:
Emelina E.I., Gendlin G.E. A modern choice for patients with hypertension: the possibility of new calcium antagonist of III generation. Rational Pharmacotherapy in Cardiology. 2015;11(5):535-542. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-5-535-542
Views:
946
Email this article 